Mu Lin

and 7 more

Abstract Background and Purpose: G-protein-coupled receptor (GPR158), an orphan receptor, is highly expressed in the medial prefrontal cortex in (mPFC) and identified as a novel therapeutic target for treating depression. Trilobatin (TLB) is a naturally-occurring food additive with potent neuroprotective properties. However, its pharmacological effects and molecular mechanisms against depression remains unknown. We explored whether TLB alleviates depression by targeting GPR158. Experimental Approach: Chronic unpredictable mild stress (CUMS)-induced depression mice model was used to explore antidepressant-like effect of TLB. GPR158-deficent mice were treated with TLB to determine whether TLB exerts its antidepressant-like effect by targeting GPR158. Key Results: TLB effectively alleviated CUMS-induced depressive-like behavior in mice. Mitophagy was contributed to the antidepressant-like effect of TLB, as evidenced by qRT-PCR array. As anticipated, TLB up-regulated autophagy associated protein expression of PFC in mice and restored mitochondrial dynamic balance, further inhibiting oxidative stress, as reflected by reducing ROS generation and increasing antioxidant enzymes. Mechanistically, GPR158 deficiency also up-regulated autophagy associated proteins expression and rejuvenated mitochondrial dynamic, further attenuating depressive-like behavior in response to CUMS insult. Most importantly, TLB directly bound to GPR158 and decreased its protein expression. Encouragingly, the promotive effect of TLB on mitophagy and its antidepressant-like effect were enhanced in GPR158-deficent mice. Conclusions and Implications: Our findings not only highlight GPR158-mediated mitophagy as a crucial pharmacological target for managing depression, but also reveal a new-found pharmacological property of TLB: serving as a novel naturally-occurring ligand of GPR158 to safeguard depression from oxidative stress by promoting mitophagy.

Jianmei Gao

and 8 more

Background and Purpose:: Peroxisome proliferator-activated receptor α and-γ (PPARα/γ) are known to play crucial roles in acute liver injury (ALI). Icariside Ⅱ (ICS Ⅱ), a natural flavonoid compound derived from Herba Epimedii, confers neuroprotection with PPARα/γ induction potency. This study was aimed to explore whether ICS Ⅱ has the capacity to protect against ALI, and if so what are the role of PPARα/γ in the beneficial effect of ICS Ⅱ on ALI. Experimental Approach: Mice challenged by D-galactosamine (GalN)/lipopolysaccharide (LPS) and Kupffer cells (KCs) upon LPS insult were used as ALI models in vivo and in vitro. PPARα/γ-deficient mice and Sirt6-deficient mice were treated with ICS Ⅱ to validate the potential targets of ICS Ⅱ on ALI. Key results: ICS Ⅱ dose-dependently improved the survival rate and liver histology, decreased ALT and AST in D-galactosamine (GalN)/lipopolysaccharide (LPS)-treated mice. Furthermore, ICS Ⅱ directly bound to PPARα/γ and increased their activities. The protective properties of ICS Ⅱ were counteracted when PPARα/γ were knocked out in GalN/LPS-induced mice and LPS-induced KCs, respectively. Mechanistically, ICS Ⅱ restored mitochondrial function, reduced oxidative stress and inflammation through activating PPARα/γ, which interacted with Sirt6 and inhibited NF-κB nuclear translocation. Intriguingly, ICS Ⅱ-evoked hepatoprotective effect and activation of PPARα/γ were largely blunted in Sirt6-deficient mice. Conclusions and implications: Our findings not only highlight PPARα/γ-SIRT6 signaling as a vital therapeutic target to combat ALI, but also reveal ICS Ⅱ may serve as a novel dual PPARα/γ agonist to safeguard ALI from the oxidation-inflammation vicious circle by coactivating SIRT6.

Linying Feng

and 8 more

Background and Purpose: Blood-brain barrier (BBB) breakdown is one of the most crucial pathological changes of cerebral ischemia-reperfusion (I/R) injury. Trilobatin (TLB), a naturally occurring food additive, exerts neuroprotective effect against cerebral I/R injury as demonstrated in our previous study. This study was designed to investigate the effect of TLB on disruption of BBB after cerebral I/R injury. Experimental Approach: Rats with focal cerebral ischemia caused by transient middle cerebral artery occlusion (MCAO) and brain microvascular endothelial cells along with human astrocytes to mimic blood brain barrier (BBB) injury caused by oxygen and glucose deprivation (OGD) followed by reoxygenation (OGD/R). Key results: The results showed that TLB effectively maintained the integrity of BBB and inhibited neuronal loss following cerebral I/R challenge. Furthermore, TLB dramatically increased tight junction proteins including ZO-1, occludin and claudin 5, as well as decreased the levels of apolipoprotein E (APOE) 4, cyclophilin A (CypA), and phosphorylated nuclear factor kappa B (NF-κB), thereby reduced proinflammatory cytokines. In addition, TLB also decreased Bax/Bcl-2 ratio and cleaved-caspase 3 level along with reduced the number of apoptotic neurons. Intriguingly, molecular docking and transcriptomics predicted MMP9 was a prominent gene evoked by TLB treatment. Furthermore, the protective effect of TLB on OGD/R-induced the loss of BBB integrity in human brain microvascular endothelial cell and astrocyte co-cultures in vitro was markedly reinforced by knockdown of MMP9. Conclusions and implications: Our findings reveal a novel property of TLB: saving BBB disruption following cerebral I/R via targeting MMP9 and inhibiting APOE4/CypA/NF-κB axis.

Linying Feng

and 9 more

Background and Purpose: Blood-brain barrier (BBB) breakdown is one of the most crucial pathological changes of cerebral ischemia-reperfusion (I/R) injury. Trilobatin (TLB), a naturally occurring food additive, exerts neuroprotective effect against cerebral I/R injury as demonstrated in our previous study. This study was designed to investigate the effect of TLB on disruption of BBB after cerebral I/R injury. Experimental Approach: Rats with focal cerebral ischemia caused by transient middle cerebral artery occlusion (MCAO) and brain microvascular endothelial cells along with human astrocytes to mimic blood brain barrier (BBB) injury caused by oxygen and glucose deprivation (OGD) followed by reoxygenation (OGD/R). Key results: The results showed that TLB effectively maintained the integrity of BBB and inhibited neuronal loss following cerebral I/R challenge. Furthermore, TLB dramatically increased tight junction proteins including ZO-1, occludin and claudin 5, as well as decreased the levels of apolipoprotein E (APOE) 4, cyclophilin A (CypA), and phosphorylated nuclear factor kappa B (NF-κB), thereby reduced proinflammatory cytokines. In addition, TLB also decreased Bax/Bcl-2 ratio and cleaved-caspase 3 level along with reduced the number of apoptotic neurons. Intriguingly, molecular docking and transcriptomics predicted MMP9 was a prominent gene evoked by TLB treatment. Furthermore, the protective effect of TLB on OGD/R-induced the loss of BBB integrity in human brain microvascular endothelial cell and astrocyte co-cultures in vitro was markedly reinforced by knockdown of MMP9. Conclusions and implications: Our findings reveal a novel property of TLB: saving BBB disruption following cerebral I/R via targeting MMP9 and inhibiting APOE4/CypA/NF-κB axis.